European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2026
Neuroimaging predictors of cognitive benefits after virtual reality-based cognitive remediation in mood or schizophrenia spectrum disorders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Damgaard Viktoria, Søndergaard Ida Kruse, Jespersen Andreas Elleby, Lumbye Anders, Vinberg Maj, Glenthøj Louise Birkedal, Nordentoft Merete, Sankar Anjali, Macoveanu Julian, Miskowiak Kamilla Woznica
Аннотация
Cognitive impairment is a core feature across mood disorders (MD) and schizophrenia spectrum disorders (SSD), but effective replicated pro-cognitive treatments are lacking. Identifying neuroimaging biomarkers that predict treatment efficacy can aid development of more effective and personalized treatment strategies. Virtual reality-based cognitive remediation therapy (VR-CRT) improves cognition and increases task-related neurocircuitry activity in the dorsal prefrontal cortex (dPFC) in MD or SSD. This study investigates if pre-treatment functional and structural neuroimaging features can predict cognitive benefits after VR-CRT. Thirty-six cognitively impaired individuals with clinically stable MD or SSD underwent neuropsychological assessment and magnetic resonance imaging (MRI) at baseline and after completion of either a four-week VR-CRT intervention (n = 20) or VR control treatment (n = 16). Linear regression analyses were conducted to assess if pre-treatment dPFC neurocircuitry activity and thickness were associated with greater VR-CRT-related benefits on global cognition. Lower baseline activity in the left superior frontal gyrus during memory encoding was associated with greater VR-CRT-related improvements in global cognition at treatment completion (β = -1.40, 95% CI [-2.45; -0.35], p = 0.01) but not at three-months follow-up (p = 0.16). Cortical thickness in the dPFC was not related to treatment effects on cognition (ps≥0.28). In conclusion, lower pre-treatment dPFC neurocircuitry activity is associated with greater cognitive benefits after VR-CRT across individuals with MD or SSD. If replicated, dPFC hypoactivation may represent a transdiagnostic neural biomarker predicting enhanced cognitive gains from VR-based cognitive training.